Summary

Global Liquid Biopsy Market Size

Liquid Biopsy Market is expected to reach US$ 15.46 billion in 2033 from US$ 4.29 billion in 2024, with a CAGR of 15.30% from 2025 to 2033. The development of automated liquid biopsy platforms, the growing need for individualized medicine and therapies, and the rising incidence of cancer are some of the major drivers propelling the market's expansion.


Liquid Biopsy Industry Overview

A non-invasive diagnostic method called liquid biopsy examines blood or other body fluids to find DNA fragments produced by tumors, cancer biomarkers, or genetic abnormalities. Liquid biopsy provides a less intrusive and more accessible alternative to standard biopsy, which necessitates tissue samples, for early cancer identification, tracking the effectiveness of treatment, and detecting recurrence. Its main applications include the detection of malignancies such as colorectal, lung, and breast cancers and the evaluation of genetic alterations for individualized treatment regimens. Compared to traditional tissue biopsies, the technique is becoming more popular since it can offer real-time information and lessen patient suffering.

Liquid biopsy is growing because of a number of variables. The necessity for non-invasive, early detection techniques has been brought to light by the rising incidence of cancer worldwide. Liquid biopsy is a desirable substitute for traditional tissue biopsy since it makes it possible to identify genetic alterations, cancer biomarkers, and tumor DNA fragments with little discomfort. The accuracy and sensitivity of liquid biopsy have been improved by technological developments in sequencing and analysis techniques, which has increased its uptake even further. Key factors propelling this market are also the move toward personalized therapy, which necessitates accurate genetic insights for customized treatments, and the rising need for real-time tracking of cancer progression.


Growth Drivers for the Liquid Biopsy Market

Increased Interest in Non-Invasive Prenatal Testing (NIPT)

Amniocentesis and chorionic villus sampling (CVS), two common prenatal testing techniques, have a slight risk of complications, including miscarriage. NIPT provides a non-invasive prenatal screening option by examining cell-free fetal DNA (cffDNA) that is present in the mother's blood. For example, amniocentesis can be done anywhere between 15 weeks of pregnancy and delivery, and in skilled hands, there is a 0.13% possibility of losing singletons, according to the National Library of Medicine. This is consistent with the 1 in 100 chance of developing amniocentesis after 15 weeks of pregnancy. Many expectant parents prefer this non-invasive method since it is safe and lowers the chance of complications from the operation.

Furthermore, trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), and trisomy 21 (Down syndrome) are among the frequent prenatal chromosomal abnormalities that NIPT has shown a high degree of accuracy in identifying. Additionally, NIPT assays based on liquid biopsies have a high sensitivity and specificity for detecting fetal genetic disorders, giving pregnant parents trustworthy information on the health of their unborn child. For example, Novacyt subsidiary Yourgene Health partnered with Laboriad to launch Morocco's first non-invasive prenatal testing (NIPT) platform in November 2023.

In addition, NIPT offers early information on the genetic health of the fetus and can be carried out as early as 9–10 weeks into pregnancy. When chromosomal anomalies are discovered early, pregnant parents can make well-informed decisions regarding their pregnancy, take into account different diagnostic procedures, or get ready for the delivery of a child with special needs. Additionally, NIPT offers early insights into the genetic health of the fetus and can be carried out as early as 9–10 weeks into pregnancy. When chromosomal anomalies are discovered early, pregnant parents can make well-informed decisions regarding their pregnancy, take into account different diagnostic procedures, or get ready for the delivery of a child with special needs.


Growing Clinical Trials and R&D Activities

The frequency of cancer screening, drug trial optimization, and therapy selection is increasing due to the growing technological breakthroughs in liquid biopsies. Numerous government organizations and businesses are concentrating on funding research and development in order to carry out liquid biopsy clinical studies. For example, Codetta Biosciences raised $15 million in a Series A funding round headed by Anzu Partners in June 2023. The money also came from VC23 LLC and Genoa Ventures. With the money, Codetta intends to accelerate the development of their multi-omic dsPCR platform for liquid biopsy and quickly grow its R&D, engineering, marketing, and business administration teams.

Clinical trials also provide a means of assessing the effectiveness of new liquid biopsy platforms and technologies. Next-generation sequencing (NGS) platforms, digital PCR systems, and other cutting-edge technologies that improve the sensitivity, specificity, and scalability of liquid biopsy assays are made possible by research and development investments. These developments can be validated in actual clinical settings through clinical studies, opening the door for their commercialization and broad use. The next-generation sequencing (NGS) and optical mapping platform, for example, was introduced in April 2024 by NewBiologix SA, a technology innovation company dedicated to filling manufacturing gaps in gene therapy. This innovative suite of technologies will offer the biopharmaceutical industry comprehensive genomic analysis services. These elements are also influencing the market share of liquid biopsies.


Growing Cancer Prevalence

The importance of early cancer identification and monitoring is increasing as a result of rising cancer incidence worldwide. For example, the WHO predicted that 9.7 million people will die from cancer and 20 million new cases would be diagnosed in 2022. 53.5 million people were predicted to live five years after receiving a cancer diagnosis. Approximately one in five people will have cancer at some point in their lives. In 2050, there will likely be over 35 million additional cases of cancer, a 77% increase from the 20 million predicted in 2022. A non-invasive technique for identifying circulating tumor biomarkers in physiological fluids like blood or urine is liquid biopsies. These biomarkers include circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Clinicians can identify cancer sooner and more accurately track the course of the disease with the use of these biomarkers, which can offer important insights about the presence, progression, and genetic profile of cancer. For example, researchers reported on a liquid biopsy multicancer early detection test that uses a novel platform to evaluate DNA methylation at the 2023 American Association of Cancer Research Annual Meeting. The new method captures methylation cfDNA molecules without any chemical or enzymatic treatment, whereas traditional procedures need chemical treatment of DNA prior to sequencing.


Challenges in the Liquid Biopsy Market

Regulatory Hurdles

The market for liquid biopsy is severely hampered by regulatory obstacles. The FDA and other regulatory bodies demand thorough clinical validation to guarantee accuracy, dependability, and safety, which makes the clearance procedure for liquid biopsy tests drawn out and complicated. Liquid biopsy methods are made more difficult by the absence of established protocols. These strict rules impede broad acceptance, raise development costs, and postpone the release of new tests, especially in markets with less developed regulatory frameworks.


High Cost

Costs are a significant obstacle in the market for liquid biopsies. Production expenses are significant due to the high cost of the specialized equipment and technology needed for liquid biopsy tests. Because of this, the tests are more expensive, particularly for patients in underdeveloped or low-income areas. The expense of clinical validation and research for regulatory approval further adds to the financial strain. Particularly in healthcare systems with tight budgets or no reimbursement coverage, these exorbitant expenses may prevent liquid biopsy from being widely used.


Liquid biopsy kits offer numerous benefits, driving strong global demand in the market.

Liquid biopsy kits, known for simplicity, are needed in medical labs and research. Their high sensitivity detects minute cancer cell amounts in blood, crucial for rare cases. High specificity prevents fake positives, distinguishing cancers from normal cells. Cost-effectiveness makes them low-cost. Their vast applicability throughout cancer supports flexible analysis and tracking. Amidst growing call for non-invasive cancer prognosis, liquid biopsy's growth is fueled, solidifying the pivotal role of those kits in meeting healthcare demands.

The high share of cancer therapeutic applications in the global liquid biopsy industry is driven by its ability to offer real-time insights into tumor dynamics.

Liquid biopsy transforms cancer care through non-invasive tracking and early detection of resistance. Analyzing ctDNA or CTCs in blood allows well timed changes to remedy, supported by customized decisions through genomic profiling. The approach excels in detecting minimum residual ailment, allowing proactive interventions to prevent recurrence. So, liquid biopsy optimizes treatment, tailors treatment options, and complements real-time records for advanced patient outcomes. Its non-invasive nature, regarding a simple blood draw, boosts compliance and facilitates repeated sampling, decreasing soreness and risks associated with conventional biopsies.

Liquid biopsy is an alternative method for cancer (Lung, Breast, Colorectal, Prostate, Liver, and Other) detection that allows for screening, therapy selection, and disease prognosis. It's beneficial for patients who cannot undergo invasive tumor biopsies. High prevalence and demand for minimally invasive therapies drive the cancer liquid biopsy market.


Circulating tumor cells (CTCs) are experiencing continuous growth in the market.

Advances in CTC detection, the use of microfluidic devices, antibody-based strategies, and sequencing, enhance uncommon CTC evaluation precision. This progress deepens understanding of CTC biology, revealing molecular profiles, heterogeneity, and metastatic mechanisms. This knowledge informs innovative diagnostic and healing strategies. CTCs are pivotal prognostic and predictive biomarkers, imparting insights into cancer recurrence, metastasis, and treatment response. Their excessive sensitivity makes them powerful indicators of minimal residual disorder, enabling proactive interventions to prevent or postpone recurrence after preliminary treatment.


Point-of-care testing (POCT) is gaining significant traction in the global market

POCT transforms liquid biopsy, imparting rapid, precise analysis at the patient's bedside for real-time diagnostic insights, prompting fast remedy selections. This improves patient care, lowering hospital stays and healthcare costs whilst decentralizing services for broader accessibility. POCT enhances convenience by doing away with travel needs and multiple testing visits, contributing to patient satisfaction. Integration with electronic health facts streamlines data change, and technological improvements enhance price-effectiveness, expanding POCT's appeal across clinical settings. Also, POCT holds ability for early cancer detection, aligning with personalised medicine trends and overcoming challenges in traditional liquid biopsy techniques.


Liquid Biopsy Market Overview by Regions

The market for liquid biopsies is growing worldwide, with North America leading the way because of its sophisticated healthcare system and widespread use of new technology. Europe comes next, propelled by rising cancer research and prevalence. Growing access to healthcare and rising cancer rates in emerging economies are driving the Asia-Pacific region's rapid growth.


United States Liquid Biopsy Market

The market for liquid biopsies in the US is expanding quickly due to rising cancer rates and the need for early, non-invasive diagnostic techniques. Compared to traditional tissue biopsy, liquid biopsy is less intrusive and allows for early identification, real-time monitoring, and individualized treatment. The market is expanding as a result of improvements in liquid biopsy test sensitivity and genomic technology advancements. Demand is further increased by the move to personalized medicine, which depends on accurate genetic information. The adoption and growth of liquid biopsy technologies in the United States are also significantly influenced by a robust healthcare system, funding for research, and regulatory backing from organizations like the FDA.


Germany Liquid Biopsy Market

The rising need for non-invasive diagnostic techniques and rising cancer occurrences are driving growth in Germany's liquid biopsy industry. The use of liquid biopsy for early cancer identification and individualized treatment is facilitated by the nation's sophisticated healthcare infrastructure and strong research emphasis. Growth in the market is also supported by improvements in genetic testing technology and growing demand for precision medicine. Furthermore, Germany's healthcare policies and regulatory frameworks support the adoption of cutting-edge diagnostic technologies, which propels the region's liquid biopsy market.


India Liquid Biopsy Market

The market for liquid biopsies in India is expanding quickly due to the growing incidence of cancer and growing awareness of early detection. Liquid biopsy is becoming more and more used as a non-invasive diagnostic technique to track the course of cancer and customize treatment plans. Further driving market expansion are developments in genetic testing technologies and an increasing emphasis on precision medicine. The use and growth of liquid biopsy solutions in India is also being aided by government initiatives, better healthcare infrastructure, and easier access to specialized treatment.


UAE Liquid Biopsy Market

The rising incidence of cancer and the rising need for non-invasive diagnostic techniques are driving the growth of the liquid biopsy market in the United Arab Emirates. A move toward customized care and improvements in genetic testing technology have made liquid biopsies the go-to method for early cancer identification, monitoring, and therapy. Innovative diagnostic solutions are adopted in the UAE because of its highly developed healthcare infrastructure, strong research focus, and high levels of healthcare awareness. The UAE's liquid biopsy industry is also expanding as a result of government programs that encourage healthcare innovation and better access to specialist treatment.


Product
1. Kits & Reagents
2. Platforms & Instruments
3. Services


Application
1. Cancer Therapeutic Application
2. Reproductive Health
3. Other Therapeutic


Circulating Biomarkers
1. Circulating Tumour Cell
2. Circulating Tumour DNA
3. Cell-free DNA


End-User
1. Hospitals
2. Diagnostic Laboratories
3. Point-of-care Testing
4. Academic Institutes
5. Others


Country
1. Americas
1.1 United States
1.2 Canada
1.3 Mexico
1.4 Brazil
2. Europe
2.1 United Kingdom
2.2 Germany
2.3 France
2.4 Italy
2.5 Spain
2.6 Netherlands
3. Asia – Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Australia
4. Middle East & Africa
4.1 United Arab Emirates
4.2 South Africa
5. Rest of the World


All companies have been covered from 3 viewpoints:
• Overview
• Recent Development
• Revenue


Company Analysis:
1. F. Hoffmann-La Roche Ltd.
2. Bio-Rad Laboratories
3. Thermo Fisher Scientific Inc.
4. Johnson & Johnson
5. Biocept Inc.
6. Guardant Health
7. Illumina, Inc.
8. Laboratory Corporation of America Holdings
9. QIAGEN N.V.
10. Exact Sciences Corporation


Key Questions Answered in Report:

1. How big is the liquid biopsy industry?
The global liquid biopsy devices market size was valued at US$ 3.72 billion in 2024 and is expected to reach US$ 15.45 billion in 2033.

2. What is the liquid biopsy growth rate?
The global liquid biopsy market is expected to expand at a compound annual growth rate (CAGR) of 17.14% from 2025 to 2033.

3. Who are the key players in liquid biopsy industry?
F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Thermo Fisher Scientific Inc., Johnson & Johnson, Biocept Inc., Guardant Health, Illumina, Inc., Laboratory Corporation of America Holdings, QIAGEN N.V, and Exact Sciences Corporation represent the primary contenders in the worldwide liquid biopsy sector.

4. What are the factors driving the liquid biopsy industry?
Growth drivers of liquid biopsy devices include increasing cancer prevalence, advancements in non-invasive diagnostic technology, rising demand for early detection, personalized medicine, improved accuracy, and growing adoption in clinical settings.

5. Which Region held the largest market share in the liquid biopsy industry?
North America is expected to hold the largest market share in the industry.

6. What segments are covered in the liquid biopsy market report?
Product, Application, Circulating Biomarkers, End User and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Liquid Biopsy Market
6. Market Share Analysis
6.1 By Product
6.2 By Application

6.2.1 By Cancer Type

6.3 By Circulating Biomarker
6.4 By End Users
6.5 By Country


7. Product
7.1 Kits & Reagents
7.2 Platforms & Instruments
7.3 Services


8. Application
8.1 Cancer Therapeutic Application

8.1.1 By Cancer Type
8.1.1.1 Lung Cancer
8.1.1.2 Breast Cancer
8.1.1.3 Colorectal Cancer
8.1.1.4 Prostate Cancer
8.1.1.5 Liver Cancer
8.1.1.6 Other Cancers

8.2 Reproductive Health
8.3 Other Therapeutic


9. Circulating Biomarker
9.1 Circulating Tumor Cell
9.2 Circulating Tumor DNA
9.3 Cell-free DNA (cfDNA)
9.4 Extracellular Vesicles
9.5 Other Biomarkers


10. End User
10.1 Hospitals
10.2 Diagnostic Laboratories
10.3 Point-of-care Testing
10.4 Academic Institutes
10.5 Others


11. Country
11.1 Americas

11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.1.4 Brazil

11.2 Europe

11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands

11.3 Asia – Pacific

11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia

11.4 Middle East & Africa

11.4.1 United Arab Emirates
11.4.2 South Africa

11.5 Rest of the World


12. Porter’s Five Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Rivalry
12.4 Threat of New Entrants
12.5 Threat of Substitutes


13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat


14. Company Analysis
14.1 F. Hoffmann-La Roche Ltd.

14.1.1 Overview
14.1.2 Recent Development
14.1.3 Financial Insight

14.2 Bio-Rad Laboratories

14.2.1 Overview
14.2.2 Recent Development
14.2.3 Financial Insight

14.3 Thermo Fisher Scientific Inc.

14.3.1 Overview
14.3.2 Recent Development
14.3.3 Financial Insight

14.4 Johnson & Johnson

14.4.1 Overview
14.4.2 Recent Development
14.4.3 Financial Insight

14.5 Biocept Inc.

14.5.1 Overview
14.5.2 Recent Development
14.5.3 Financial Insight

14.6 Guardant Health

14.6.1 Overview
14.6.2 Recent Development
14.6.3 Financial Insight

14.7 Illumina, Inc.

14.7.1 Overview
14.7.2 Recent Development
14.7.3 Financial Insight

14.8 Laboratory Corporation of America Holdings

14.8.1 Overview
14.8.2 Recent Development
14.8.3 Financial Insight

14.9 QIAGEN N.V

14.9.1 Overview
14.9.2 Recent Development
14.9.3 Financial Insight

14.10 Exact Sciences Corporation

14.10.1 Overview
14.10.2 Recent Development
14.10.3 Financial Insight